DSM-Firmenich has reported flat overall growth for 2025 after seeing a lacklustre final quarter of trading.
The Euronext-listed fragrance and flavour company’s 2025 sales reached €9.034bn, down from the €9,054bn reported just one year prior.
DSM-Firmenich also reported organic sales growth of 3% for the year.
Earnings were impacted by a 4% sales decline to €2.1bn in Q4, down from €2.2bn recorded during the same quarter in 2024.
On 9 February 2026, DSM-Firmenich announced its intentions to divest its Animal Nutrition & Health business to CVC Capital Partners for an estimated €2.2bn, as it doubled down on its nutrition, health and beauty offering.
“The recently announced divestment of Animal Nutrition & Health marks the final step in executing our strategic roadmap to becoming a leading consumer-focused company in nutrition, health and beauty,” said Dimitri de Vreeze, CEO of DSM-Firmenich.
“This is an important milestone for the company.
“It enables us to fully focus on our core strengths and the execution of our strategy to deliver on our mid-term ambitions, while creating sustainable long-term value for all stakeholders.”
DSM-Firmenich’s Perfumery & Beauty division delivered organic sales growth of 3% in 2025.
Its Fine Fragrances division delivered high single-digit growth, whereas Consumer Fragrances and Ingredients delivered mid-single-digit growth.
Beauty & Care, meanwhile, was impacted by weakness in sun filters – ingredients which integrate into the oil phase of sun protection formulations.
On a regional basis, the business saw strong growth in the Middle East, Asia and Europe, with softness in North America and Latin America.
De Vreeze continued: “From a business perspective, we made good progress in improving the performance of our three continuing business operations.
“Our innovative solutions play a critical role in essential, everyday consumer products, demonstrating the strength and resilience of our portfolio, particularly against the more challenging macroeconomic backdrop in the second half of 2025.”
Looking ahead, DSM-Firmenich’s mid-term financial ambitions include organic sales growth of between 5% to 7%, and an adjusted EBITDA margin of between 22% to 23%.
“We are well-positioned for 2026, supported by innovation-driven growth, continued delivery of sales synergies, continued focus on cash generation and capital discipline,” said de Vreeze.
“This is further underpinned by the newly announced €500m share repurchase programme, and maintaining a €2.50 dividend per share, with a stable to preferably rising dividend policy going forward.”
Related content:
- DSM-firmenich share price rises after Q2 earnings beat expectations
- dsm-firmenich and Inscripta announce strategic partnership to drive biotech innovations in well-ageing skincare
- DSM-Firmenich names new Fine Fragrances President to lead business ‘into a new era’
Featured companies
- Companies:
- DSM-Firmenich